{"sheets": {"分析サマリー": [["会社名", "G-窪田製薬HD"], ["コード", "4596"], ["表題", "業績予想に関するお知らせ"], ["日付", "20260210"]], "財務データ一覧": [["勘定科目", "当期", "前期", "増減額", "増減率"], ["売上高", null, 27000000, null, null], ["営業収益", null, -1345000000, null, null], ["税引前当期純利益", null, -1333000000, null, null], ["当期純利益", null, -1333000000, null, null], ["親会社株主に帰属する当期純利益", null, -1333000000, null, null], ["1株当たり当期純利益", null, -23.65, null, null]], "XBRLデータ（Raw）": [["勘定科目", "XBRL要素名", "名前空間", "期間", "数値", "原文", "単位", "コンテキスト"], ["ReportingDateOfFinancialForecastCorrection", "ReportingDateOfFinancialForecastCorrection", "tse-ed-t", "当期末", null, "2026年2月10日", null, "CurrentYearInstant"], ["CompanyName", "CompanyName", "tse-ed-t", "当期末", null, "窪田製薬ホールディングス株式会社", null, "CurrentYearInstant"], ["TitleRepresentative", "TitleRepresentative", "tse-ed-t", "当期末", null, "代表取締役会長、社長兼最高経営責任者", null, "CurrentYearInstant"], ["NameRepresentative", "NameRepresentative", "tse-ed-t", "当期末", null, "窪田　良", null, "CurrentYearInstant"], ["SecuritiesCode", "SecuritiesCode", "tse-ed-t", "当期末", null, "45960", null, "CurrentYearInstant"], ["TitleInquiries", "TitleInquiries", "tse-ed-t", "当期末", null, "広報", null, "CurrentYearInstant"], ["NameInquiries", "NameInquiries", "tse-ed-t", "当期末", null, "IR", null, "CurrentYearInstant"], ["Tel", "Tel", "tse-ed-t", "当期末", null, "03-6550-8928", null, "CurrentYearInstant"], ["DocumentName", "DocumentName", "tse-ed-t", "当期末", null, "業績予想に関するお知らせ", null, "CurrentYearInstant"], ["NoticeOfForecastCorrection", "NoticeOfForecastCorrection", "tse-ed-t", "当期末", null, "2025年12月期(2025年１月１日～2025年12月31日)の通期連結業績予想につきまして、下記のとおりお知らせいたします。", null, "CurrentYearInstant"], ["売上高", "NetSales", "tse-ed-t", "予想", 21000000, "21", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["営業収益", "OperatingRevenue1", "tse-ed-t", "予想", -877000000, "877", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["税引前当期純利益", "IncomeBeforeIncomeTaxes", "tse-ed-t", "予想", -659000000, "659", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["当期純利益", "ProfitLoss", "tse-ed-t", "予想", -659000000, "659", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["親会社株主に帰属する当期純利益", "ProfitLossAttributableToOwnersOfParent", "tse-ed-t", "予想", -659000000, "659", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["1株当たり当期純利益", "EarningsPerShare", "tse-ed-t", "予想", -11.69, "11.69", "JPYPerShares", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["売上高", "NetSales", "tse-ed-t", "前期", 27000000, "27", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["営業収益", "OperatingRevenue1", "tse-ed-t", "前期", -1345000000, "1,345", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["税引前当期純利益", "IncomeBeforeIncomeTaxes", "tse-ed-t", "前期", -1333000000, "1,333", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["当期純利益", "ProfitLoss", "tse-ed-t", "前期", -1333000000, "1,333", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["親会社株主に帰属する当期純利益", "ProfitLossAttributableToOwnersOfParent", "tse-ed-t", "前期", -1333000000, "1,333", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["1株当たり当期純利益", "EarningsPerShare", "tse-ed-t", "前期", -23.65, "23.65", "JPYPerShares", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["ReasonForForecastCorrection", "ReasonForForecastCorrection", "tse-ed-t", "当期", null, "当社グループは、近視および眼疾患治療の革新を目指し、以下の通り事業を推進しております。「Kubota Glass」事業は、国内での認知度向上と、アジア・欧州を中心とした海外市場への販路拡大に注力しております。2025年12月期は、本格的な普及に向けたマーケティング活動および次世代機の開発を継続し、事業収益は21百万円となる見込みです。「エミクススタト塩酸塩」事業は、スターガルト病等の適応症に対し、蓄積された臨床データの解析と、グローバルな提携パートナー候補との協議を継続しております。海外でのコンパッショネートユース制度の活用等による早期の収益化を目指しております。損益については、上記の先行投資および研究開発費（R&D）の計上により、営業損失は877百万円となる見通しです。一方、営業外収益の計上により、当期利益以下の損失幅は営業利益に比して縮小する見込みです。", null, "CurrentYearDuration"], ["FiscalYearEnd", "FiscalYearEnd", "tse-ed-t", "当期末", null, "2025-12-31", null, "CurrentYearInstant"]]}}